Literature DB >> 3571559

Treatment of epidermolysis bullosa acquisita with cyclosporine.

S M Connolly, H M Sander.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3571559     DOI: 10.1016/s0190-9622(87)80239-6

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  8 in total

Review 1.  Epidermolysis bullosa acquisita.

Authors:  Rishu Gupta; David T Woodley; Mei Chen
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 2.  Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen.

Authors:  Mei Chen; Gene H Kim; Lori Prakash; David T Woodley
Journal:  Autoimmunity       Date:  2011-09-28       Impact factor: 2.815

Review 3.  Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management.

Authors:  Minhee Kim; Luca Borradori; Dédée F Murrell
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

5.  Epidermolysis bullosa acquisita--successful treatment with colchicine.

Authors:  M Megahed; K Scharffetter-Kochanek
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

Review 6.  Autoimmunity to type VII collagen: epidermolysis bullosa acquisita.

Authors:  David T Woodley; Jennifer Remington; Mei Chen
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

7.  Therapy of autoimmune bullous diseases.

Authors:  Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

8.  Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.

Authors:  Ralf J Ludwig
Journal:  ISRN Dermatol       Date:  2013-07-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.